New drug cocktail aims to shrink Hard-to-Treat lung tumors before surgery
NCT ID NCT07229339
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug zipalertinib, given together with standard chemotherapy, can shrink tumors in people with a specific genetic type of non-small cell lung cancer before they have surgery. The study plans to enroll 16 adults with stage II to IIIB disease whose tumors have certain EGFR mutations. The main goal is to see how many tumors have a major response (less than 10% viable cancer cells left) after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zipalertinib combined with carboplatin and pemetrexed
- What this could lead to
- If successful, this could point toward a more effective pre-surgery treatment for certain hard-to-treat lung cancers, potentially improving surgical outcomes.
- What could go wrong
- This is a very small early-phase trial with only 16 people, so results may not apply broadly. The drug combination also carries typical chemotherapy side effects like fatigue, nausea, and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized lung cancer trial halted early, but shows promise
- New drug combo aims to shrink lung tumors better
- Lung cancer trial asks: is it better to start with immunotherapy alone?
- Targeted pill may keep EGFR lung cancer from returning after surgery
- New combo therapy aims to keep lung cancer from returning after surgery